WRLD A.LIVE

23:003 reports

• Subcutaneous RYBREVANT®▼ (amivantamab) demonstrates 77% overall response rate in first-line treatment of patients with certain types of advanced head and neck cancer The Manila Times
• Trial shows new treatment could shrink tumours for those with complex and aggressive cancers The Independent
• Atirmociclib extends PFS by three months in endocrine-resistant mBC FirstWord Pharma

22:001 report

• KEYNOTE-564 at ESMO 2026: Final Analysis of Adjuvant Pembrolizumab in Clear Cell RCC Oncodaily

21:003 reports

• Scientists discover how pancreatic cancer rewrites its DNA to escape treatment Science Daily
• Scientists discover how pancreatic cancer rewrites its DNA to escape treatment Science Daily
• ‘Really terrified’: how a blood test could spare cancer patients an agonising wait South China Morning Post

20:001 report

• When a Burn Scar Invades the Brain: A Case Report of Advanced Marjolin Ulcer of the Scalp Cureus

19:002 reports

• Pfizer Sees Path Forward for Cancer Drug Despite Trial Failure Bloomberg.com
• Beyond Live Streaming: Tango Gives Back by Supporting Cancer Detection in Ukraine The Manila Times

18:00nothing heard

17:001 report

• Yakup Ergün Discusses Final Overall Survival Results From the postMONARCH Trial in Advanced Breast Cancer Oncodaily

16:004 reports

• Pfizer's Atirmociclib Held Off Breast Cancer Progression for 9.4 Months Versus 6.6 After CDK4/6 Drugs Stopped Working Medical Daily
• Kazuki Nozawa: Final Overall Survival Analysis from the Phase III postMONARCH Trial Oncodaily
• Final postMONARCH OS Favors Abemaciclib Plus Fulvestrant in HR+/HER2–Advanced Breast Cancer OncLive
• LITESPARK-012 at ESMO 2026: Belzutifan or Quavonlimab Plus Pembrolizumab and Lenvatinib in Advanced RCC Oncodaily

15:001 report

• POP-DURVA: Short-Course Durvalumab Remodels the Immune Microenvironment but Rarely Produces pCR in Stage I TNBC Oncodaily

14:00nothing heard

13:00nothing heard

12:00nothing heard

11:00nothing heard

10:00nothing heard

09:00nothing heard

08:001 report

• ESMO26: Imfinzi-Padcev duo lowers bladder cancer mortality risk by 42% FirstWord Pharma

07:00nothing heard

06:00nothing heard

05:001 report

• Cervical Intraepithelial Neoplasia in the Public Health System of Bahia, Brazil: A Descriptive Time-Series Study (2014-2023) Cureus

04:002 reports

• First-Line Dato-DXd Improves Intracranial Outcomes in Immunotherapy-Ineligible TNBC With Brain Metastases OncLive
• Investigating Novel Immunotherapy Targets in Metastatic RCC Targeted Oncology

03:003 reports

• Is Active Surveillance Feasible for Esophageal Cancer? Medscape
• Is Active Surveillance Feasible for Esophageal Cancer? Medscape
• In situ immunotherapy shows encouraging survival findings in prostate cancer Urology Times

02:008 reports

• A simple saliva test could help families avoid cancer. So why aren't more people getting it? Business Insider
• ESMO: Chasing Keytruda, AstraZeneca’s Imfinzi pitches its own Padcev combos in bladder cancer Fierce Pharma
• Perioperative Nivolumab Plus Neoadjuvant Chemotherapy Misses Co-Primary End Points in Muscle-Invasive Bladder Cancer OncLive
• VOLGA: Durvalumab plus enfortumab vedotin improves EFS, OS in MIBC Urology Times
• Pembrolizumab Plus Radiation Fails to Improve Recurrence-Free Survival in Early-Stage High-Intermediate–Risk dMMR Endometrial Cancer OncLive
• Durvalumab Plus Enfortumab Vedotin Improves Survival in Cisplatin-Ineligible MIBC OncLive
• Perioperative Imfinzi plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer AstraZeneca
• Phase III NIAGARA at ESMO 2026: Molecular Subtypes and Treatment Outcomes With Perioperative Durvalumab in MIBC Oncodaily

01:00nothing heard

00:001 report

• BEATcc at ESMO 2026: Atezolizumab Extends Overall Survival to 31.9 Months in Advanced Cervical Cancer Oncodaily